In summary, our current study found that the anti-tumor effect of CHI was partly depended on the expression of HDAC1 in MM cells and CHI combined with BTZ exhibited synergistic effect in antagonizing MM cell growth in vitro and in vivo. Here, HDAC1 is linked to Miyoshi myopathy.